A pancreatic pill proves pan-RAS is druggable. Lung and colon will price the claim

Pancreatic adenocarcinoma was the right disease to prove this mechanism and the wrong one to size it. KRAS is mutated in nearly all pancreatic cancers ^[2], which is why the label requires no test to identify a specific RAS mutation before prescribing ^[4]: the tumor type is the biomarker. The control arm was also about as low as regulated oncology gets, a median of 6.7 months on standard chemotherapy against 13.2 months on the drug, a gain of 6.5 months and just short of a doubling ^[5][19]. Adenocarcinoma accounts for 90% to 95% of pancreatic cases ^[12], so the enrolled population sits close to the whole disease.

In lung, colorectal and ovarian cancer, KRAS mutations turn up in many cases rather than nearly all ^[2]. That restores two things this trial never had to face: a diagnostic gate deciding who is eligible, and comparators that already deliver more than months. Revolution Medicines is running daraxonrasib through late-stage lung trials ^[13], and that is where the druggability claim meets a harder arithmetic.

The pricing works the same way. At $39,800 per 30-day supply ^[7], list cost is roughly $484,000 a year ^[21] and about $525,000 across the 13.2-month median ^[20]. In this indication, mortality is the cost control. Five-year survival has sat at 13% for three years while all cancers combined reached 70% ^[10], a 57-point gap ^[23], and about 80% of patients are metastatic at diagnosis, roughly 54,000 of the 67,530 Americans expected to be diagnosed in 2026 ^[9][11][22]. In a cancer patients survive for years, the same monthly price compounds, and that is the conversation payers will actually have.

The platform framing deserves precise attribution. The claim that RAS mutations appear in roughly a quarter of all human cancers, and that Revolution has built a platform rather than a drug, comes from Danish Nagda, an early shareholder who told Fortune he has been "very, very bullish" on the stock ^[1][17]. The clinical read is separate: Brian Wolpin, the trial's principal investigator at Dana-Farber, said the approval gives physicians confidence that directly inhibiting RAS can make a striking difference for patients ^[15], and Anna Berkenblit of the Pancreatic Cancer Action Network called it the most significant advance yet in the disease ^[16].

On the review timeline, the Fortune account argues with itself: it reports the decision landed 6.5 months before the user-fee deadline, then says the figure is unverified and that the Breakthrough Therapy and Orphan Drug designations plus the National Priority Voucher pilot explain the compressed schedule without it ^[14][24]. What is documented is narrower than the headline number. The revenue base is similarly unresolved. An expanded access program opened in May has already reached more than 2,000 patients ^[8], and eligible insured patients may pay as little as $0 through the company's support program ^[7], so the list price tells you very little about net.